CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Poseida Therapeutics, Inc. - PSTX CFD

    2.97
    4.95%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.05
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Poseida Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 2.83
    Open* 2.76
    1-Year Change* -43.67%
    Day's Range* 2.75 - 2.98
    52 wk Range 1.54-8.82
    Average Volume (10 days) 536.85K
    Average Volume (3 months) 10.44M
    Market Cap 249.58M
    P/E Ratio -100.00K
    Shares Outstanding 95.62M
    Revenue 49.76M
    EPS -1.50
    Dividend (Yield %) N/A
    Beta 0.22
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 2.97 0.22 8.00% 2.75 2.99 2.70
    Dec 4, 2023 2.83 0.23 8.85% 2.60 2.84 2.59
    Dec 1, 2023 2.61 0.01 0.38% 2.60 2.63 2.36
    Nov 30, 2023 2.64 0.02 0.76% 2.62 2.72 2.60
    Nov 29, 2023 2.61 -0.01 -0.38% 2.62 2.75 2.59
    Nov 28, 2023 2.63 0.03 1.15% 2.60 2.69 2.56
    Nov 27, 2023 2.70 -0.04 -1.46% 2.74 2.77 2.61
    Nov 24, 2023 2.73 0.17 6.64% 2.56 2.83 2.56
    Nov 22, 2023 2.58 -0.01 -0.39% 2.59 2.76 2.52
    Nov 21, 2023 2.58 -0.08 -3.01% 2.66 2.67 2.53
    Nov 20, 2023 2.71 0.51 23.18% 2.20 2.76 2.18
    Nov 17, 2023 2.23 0.13 6.19% 2.10 2.25 2.06
    Nov 16, 2023 2.13 -0.05 -2.29% 2.18 2.18 2.03
    Nov 15, 2023 2.19 -0.08 -3.52% 2.27 2.41 2.18
    Nov 14, 2023 2.32 0.16 7.41% 2.16 2.33 2.11
    Nov 13, 2023 2.08 -0.08 -3.70% 2.16 2.18 2.03
    Nov 10, 2023 2.16 0.04 1.89% 2.12 2.21 2.00
    Nov 9, 2023 2.17 -0.06 -2.69% 2.23 2.33 2.15
    Nov 8, 2023 2.25 -0.15 -6.25% 2.40 2.40 2.22
    Nov 7, 2023 2.40 0.01 0.42% 2.39 2.51 2.36

    Poseida Therapeutics, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    21:00

    Country

    US

    Event

    Q4 2023 Poseida Therapeutics Inc Earnings Release
    Q4 2023 Poseida Therapeutics Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 130.492 31.238 0 0 0
    Revenue 130.492 31.238
    Total Operating Expense 190.438 153.149 126.549 85.533 41.989
    Selling/General/Admin. Expenses, Total 37.539 35.915 23.029 18.457 9.674
    Research & Development 152.899 136.734 103.52 60.393 29.823
    Other Operating Expenses, Total 0 6.683 1.432
    Operating Income -59.946 -121.911 -126.549 -85.533 -41.989
    Interest Income (Expense), Net Non-Operating -6.37 -3.358 -3.893 -4.072 -0.609
    Other, Net 2.858 0.295 0.667 3.078 -2.008
    Net Income Before Taxes -63.458 -124.974 -129.775 -86.527 -44.606
    Net Income After Taxes -64.002 -124.974 -129.775 -86.527 -44.404
    Net Income Before Extra. Items -64.002 -124.974 -129.775 -86.527 -44.404
    Net Income -64.002 -124.974 -129.775 -86.527 -44.404
    Income Available to Common Excl. Extra. Items -64.002 -124.974 -129.775 -86.527 -44.404
    Income Available to Common Incl. Extra. Items -64.002 -124.974 -129.775 -86.527 -44.404
    Diluted Net Income -64.002 -124.974 -129.775 -86.527 -44.404
    Diluted Weighted Average Shares 71.9537 62.2359 61.8609 61.8159 61.8159
    Diluted EPS Excluding Extraordinary Items -0.88949 -2.00807 -2.09785 -1.39975 -0.71833
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.88407 -2.32139 -2.09785 -1.39975 -0.70718
    Unusual Expense (Income) -19.5 0 1.06
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 20.013 10.343 10.051 116.306 2.7
    Total Operating Expense 47.868 49.859 43.272 44.526 44.245
    Selling/General/Admin. Expenses, Total 8.676 11.807 9.368 9.389 9.237
    Research & Development 39.192 38.052 33.904 35.137 35.008
    Operating Income -27.855 -39.516 -33.221 71.78 -41.545
    Interest Income (Expense), Net Non-Operating -2.141 -2.028 -1.975 -1.775 -1.543
    Other, Net 2.54 2.697 2.17 0.656 0.052
    Net Income Before Taxes -27.456 -38.847 -33.026 70.661 -43.036
    Net Income After Taxes -27.456 -38.847 -33.318 70.409 -43.036
    Net Income Before Extra. Items -27.456 -38.847 -33.318 70.409 -43.036
    Net Income -27.456 -38.847 -33.318 70.409 -43.036
    Income Available to Common Excl. Extra. Items -27.456 -38.847 -33.318 70.409 -43.036
    Income Available to Common Incl. Extra. Items -27.456 -38.847 -33.318 70.409 -43.036
    Diluted Net Income -27.456 -38.847 -33.318 70.409 -43.036
    Diluted Weighted Average Shares 86.7947 86.2652 86.1072 76.6884 62.7134
    Diluted EPS Excluding Extraordinary Items -0.31633 -0.45032 -0.38694 0.91812 -0.68623
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.31633 -0.45032 -0.38694 0.91812 -0.68623
    Revenue 20.013 10.343 10.051 116.306 2.7
    Unusual Expense (Income)
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 298.563 213.873 313.996 127.179 32.64
    Cash and Short Term Investments 282.493 206.325 309.152 125.318 30.395
    Cash & Equivalents 81.378 206.325 83.966 87.784 30.395
    Total Receivables, Net 9.088
    Accounts Receivable - Trade, Net 9.088
    Prepaid Expenses 4.464 5.448 3.231 1.427 2.044
    Total Assets 351.837 269.309 371.484 146.996 45.12
    Property/Plant/Equipment, Total - Net 46.671 48.227 48.322 10.858 3.416
    Property/Plant/Equipment, Total - Gross 60.147 57.364 52.917 12.867 4.431
    Accumulated Depreciation, Total -13.476 -9.137 -4.595 -2.009 -1.015
    Goodwill, Net 4.228 4.228 4.228 4.228 4.228
    Intangibles, Net 1.32 1.32 1.32 1.32 1.32
    Other Long Term Assets, Total 1.055 1.661 3.618 3.411 3.516
    Total Current Liabilities 53.885 43.335 30.025 21.855 13.025
    Accounts Payable 2.228 8.961 0.763 4.929 2.856
    Accrued Expenses 28.045 27.389 27.423 12.255 4.666
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases 0 3 0
    Other Current Liabilities, Total 23.612 6.985 1.839 1.671 5.503
    Total Liabilities 164.242 113.098 109.516 74.334 49.378
    Total Long Term Debt 58.25 29.357 29.133 26.14 19.086
    Long Term Debt 58.25 29.357 29.133 26.14 19.086
    Deferred Income Tax 0.055 0.055 0.055 0.055 0.055
    Other Liabilities, Total 52.052 40.351 50.303 26.284 17.212
    Total Equity 187.595 156.211 261.968 72.662 -4.258
    Preferred Stock - Non Redeemable, Net 0 222.173 72.46
    Common Stock 0.009 0.006 0.006 0.002 0.002
    Additional Paid-In Capital 658.596 563.064 543.842 2.689 -11.026
    Retained Earnings (Accumulated Deficit) -470.861 -406.859 -281.885 -152.221 -65.694
    Total Liabilities & Shareholders’ Equity 351.837 269.309 371.484 146.996 45.12
    Total Common Shares Outstanding 85.9642 62.5236 61.8609 61.8159 61.8159
    Other Current Assets, Total 2.518 2.1 1.613 0.434 0.201
    Short Term Investments 201.115 0 225.186 37.534 0
    Unrealized Gain (Loss) 0 0.005 0.019 0
    Other Equity, Total -0.149
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 252.664 230.195 260.696 298.563 325.129
    Cash and Short Term Investments 238.837 214.606 247.201 282.493 278.985
    Cash & Equivalents 25.503 49.911 40.144 81.378 164.807
    Short Term Investments 213.334 164.695 207.057 201.115 114.178
    Prepaid Expenses 5.155 3.683 5.058 6.982 7.677
    Total Assets 302.252 281.215 313.621 351.837 380.481
    Property/Plant/Equipment, Total - Net 42.953 44.407 46.322 46.671 48.748
    Property/Plant/Equipment, Total - Gross 60.588 60.602 61.106 60.147 61.579
    Accumulated Depreciation, Total -17.635 -16.195 -14.784 -13.476 -12.831
    Goodwill, Net 4.228 4.228 4.228 4.228 4.228
    Intangibles, Net 1.32 1.32 1.32 1.32 1.32
    Other Long Term Assets, Total 1.087 1.065 1.055 1.055 1.056
    Total Current Liabilities 76.973 49.888 48.69 53.885 48.968
    Accounts Payable 2.542 2.097 3.2 2.228 3.426
    Accrued Expenses 25.858 23.343 20.418 28.045 25.335
    Notes Payable/Short Term Debt 0 0 0 0 0
    Current Port. of LT Debt/Capital Leases
    Other Current Liabilities, Total 48.573 24.448 25.072 23.612 20.207
    Total Liabilities 178.592 145.914 156.056 164.242 164.168
    Total Long Term Debt 58.491 58.402 58.322 58.25 58.162
    Long Term Debt 58.491 58.402 58.322 58.25 58.162
    Deferred Income Tax 0.055 0.055
    Other Liabilities, Total 43.128 37.624 49.044 52.052 56.983
    Total Equity 123.66 135.301 157.565 187.595 216.313
    Common Stock 0.01 0.009 0.009 0.009 0.009
    Additional Paid-In Capital 692.792 672.736 667.262 658.596 653.991
    Retained Earnings (Accumulated Deficit) -568.942 -537.164 -509.708 -470.861 -437.543
    Unrealized Gain (Loss)
    Total Liabilities & Shareholders’ Equity 302.252 281.215 313.621 351.837 380.481
    Total Common Shares Outstanding 95.5735 86.8783 86.7589 85.9642 85.9464
    Total Receivables, Net 8.672 11.906 8.437 9.088 38.467
    Accounts Receivable - Trade, Net 8.672 11.906 8.437 9.088 38.467
    Other Equity, Total -0.2 -0.28 0.002 -0.149 -0.144
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -64.002 -124.974 -129.775 -86.527 -44.404
    Cash From Operating Activities -26.772 -102.543 -113.328 -64.518 -38.014
    Cash From Operating Activities 5.172 4.552 2.586 1.193 0.689
    Deferred Taxes -0.202
    Non-Cash Items 18.343 -2.289 8.238 11.349 5.185
    Cash Interest Paid 5.138 2.719 3.027 2.631 1.463
    Changes in Working Capital 13.715 20.168 5.623 9.467 0.718
    Cash From Investing Activities -203.334 222.384 -204.431 -42.464 -1.284
    Capital Expenditures -3.924 -2.634 -16.908 -5.156 -1.284
    Other Investing Cash Flow Items, Total -199.41 225.018 -187.523 -37.308 0
    Cash From Financing Activities 105.159 2.518 313.941 164.371 54.068
    Financing Cash Flow Items -1.45 0 3.834 4.589 13.5
    Issuance (Retirement) of Stock, Net 76.609 2.518 310.107 149.782 30.568
    Issuance (Retirement) of Debt, Net 30 0 10 10
    Net Change in Cash -124.947 122.359 -3.818 57.389 14.77
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -38.847 -64.002 -30.684 -101.093 -58.057
    Cash From Operating Activities -38.005 -26.772 -29.175 -91.053 -51.324
    Cash From Operating Activities 1.324 5.172 3.817 2.467 1.207
    Non-Cash Items 5.514 18.343 14.746 16.301 13.107
    Cash Interest Paid 1.829 5.138 3.47 1.996 0.718
    Changes in Working Capital -5.996 13.715 -17.054 -8.728 -7.581
    Cash From Investing Activities -4.415 -203.334 -117.444 -81.572 -0.743
    Capital Expenditures -0.784 -3.924 -3.664 -1.961 -0.743
    Other Investing Cash Flow Items, Total -3.631 -199.41 -113.78 -79.611 0
    Cash From Financing Activities 1.186 105.159 105.101 29.263 29.231
    Financing Cash Flow Items -0.494 -1.45 -1.45 -1.45 -1.45
    Issuance (Retirement) of Stock, Net 1.68 76.609 76.551 0.713 0.681
    Net Change in Cash -41.234 -124.947 -41.518 -143.362 -22.836
    Issuance (Retirement) of Debt, Net 0 30 30 30 30
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Fidelity Management & Research Company LLC Investment Advisor 13.6723 13003541 37251 2023-06-30 LOW
    Malin Life Sciences Holdings Corporation 12.4443 11835673 0 2023-03-15 LOW
    Astellas Pharma Inc Corporation 8.7619 8333333 8333333 2023-08-07 LOW
    Pentwater Capital Management LP Hedge Fund 6.2823 5975000 0 2023-06-30 HIGH
    Novartis Pharma AG Corporation 6.2119 5908089 0 2023-03-15 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 4.7447 4512626 2995266 2023-06-30 LOW
    Eric Ostertag Living Trust. Corporation 3.8477 3659503 0 2023-03-15 LOW
    SilverArc Capital Management, LLC Hedge Fund 3.0974 2945948 256647 2023-06-30 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.7245 2591199 243651 2023-06-30 LOW
    Ostertag (Eric) Individual Investor 2.4909 2369057 -67924 2023-03-15 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2875 1224567 718477 2023-06-30 LOW
    Millennium Management LLC Hedge Fund 1.2032 1144351 168739 2023-06-30 HIGH
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.1763 1118755 884288 2023-06-30 LOW
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 1.1685 1111372 99989 2023-06-30 MED
    Aisling Capital Management LP Investment Advisor/Hedge Fund 1.0969 1043267 0 2023-06-30 LOW
    Dimensional Fund Advisors, L.P. Investment Advisor/Hedge Fund 0.7366 700526 -53599 2023-06-30 LOW
    EcoR1 Capital, LLC Hedge Fund 0.7111 676296 -1973704 2023-06-30 LOW
    Two Sigma Investments, LP Hedge Fund 0.6568 624644 54400 2023-06-30 HIGH
    William Blair & Company, L.L.C. (Research) Research Firm 0.598 568740 534397 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 0.5678 540024 -63176 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Poseida Therapeutics, Inc. Company profile

    About Poseida Therapeutics Inc

    Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. It is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The Company's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Poseida Therapeutics Inc revenues increased from $0K to $31.2M. Net loss decreased 4% to $125M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest expense decrease of 4% to $3.4M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$2.01.

    Industry: Bio Therapeutic Drugs

    9390 Towne Centre Drive
    Suite 200
    SAN DIEGO
    CALIFORNIA 92121
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.61 Price
    -0.770% 1D Chg, %
    Long position overnight fee -0.0227%
    Short position overnight fee 0.0007%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    XRP/USD

    0.63 Price
    -0.880% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,912.50 Price
    +0.260% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    BTC/USD

    43,651.35 Price
    -0.910% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading